|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for CSNK2A2 |
 Gene summary |
| Basic gene Info. | Gene symbol | CSNK2A2 |
| Gene name | casein kinase 2, alpha prime polypeptide | |
| Synonyms | CK2A2|CSNK2A1 | |
| Cytomap | UCSC genome browser: 16q21 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001896.2, | |
| Description | CK II alpha'casein kinase II subunit alpha' | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 115442 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000070770 | ||
| HPRD : 00279 | ||
| Vega : OTTHUMG00000133488 | ||
| Protein | UniProt: P19784 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_CSNK2A2 | |
| BioGPS: 1459 | ||
| Pathway | NCI Pathway Interaction Database: CSNK2A2 | |
| KEGG: CSNK2A2 | ||
| REACTOME: CSNK2A2 | ||
| Pathway Commons: CSNK2A2 | ||
| Context | iHOP: CSNK2A2 | |
| ligand binding site mutation search in PubMed: CSNK2A2 | ||
| UCL Cancer Institute: CSNK2A2 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for CSNK2A2 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | D176 | G178D | COAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for CSNK2A2 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | D176 | G178D | -0.9323265 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for CSNK2A2 from PDB |
| Top |
| Differential gene expression and gene-gene network for CSNK2A2 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for CSNK2A2 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0007137 | Carcinoma, Squamous Cell | 1 | Biomarker |
| umls:C0037286 | Skin Neoplasms | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for CSNK2A2 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Experimental | DB07546 | [1-(6-{6-[(1-methylethyl)amino]-1H-indazol-1-yl}pyrazin-2-yl)-1H-pyrrol-3-yl]acetic acid | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of CSNK2A2 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | CCK | [1-(6-{6-[(1-METHYLETHYL)AMINO]-1H-INDAZOL-1-YL}PYRAZIN-2-YL)-1H-PYRROL-3-YL]ACETIC ACID | 3e3b | X | D176 | 4B0 | 3-(4,5,6,7-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL | 3ofm | A | D176 |
| Top |
| Conservation information for LBS of CSNK2A2 |
| Multiple alignments for P19784 in multiple species |
| LBS | AA sequence | # species | Species | D176 | KLRLIDWGLAE | 5 | Homo sapiens, Saccharomyces cerevisiae (strain ATCC 204508 / S288c), Arabidopsis thaliana, Mus musculus, Bos taurus | E115 | PALVFEYINNT | 3 | Homo sapiens, Mus musculus, Bos taurus | E115 | PALVFEYVDNV | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | E115 | PSLVFEFVNSV | 1 | Arabidopsis thaliana | F114 | TPALVFEYINN | 3 | Homo sapiens, Mus musculus, Bos taurus | F114 | TPALVFEYVDN | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | F114 | TPSLVFEFVNS | 1 | Arabidopsis thaliana | G49 | RKLGRGKYSEV | 3 | Homo sapiens, Mus musculus, Bos taurus | G49 | NKVGRGKYSEV | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | G49 | RKVGRGKYSEV | 1 | Arabidopsis thaliana | H161 | RDVKPHNVMID | 5 | Homo sapiens, Saccharomyces cerevisiae (strain ATCC 204508 / S288c), Arabidopsis thaliana, Mus musculus, Bos taurus | I117 | LVFEYINNTDF | 3 | Homo sapiens, Mus musculus, Bos taurus | I117 | LVFEYVDNVDF | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | I117 | LVFEFVNSVDF | 1 | Arabidopsis thaliana | I175 | KKLRLIDWGLA | 4 | Homo sapiens, Saccharomyces cerevisiae (strain ATCC 204508 / S288c), Mus musculus, Bos taurus | I175 | RKLRLIDWGLA | 1 | Arabidopsis thaliana | I96 | GGTNIIKLIDT | 3 | Homo sapiens, Mus musculus, Bos taurus | I96 | GHANIIHLFDI | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | I96 | GGPNIVKLYDI | 1 | Arabidopsis thaliana | K69 | ERVVVKILKPV | 3 | Homo sapiens, Mus musculus, Bos taurus | K69 | VKIVIKMLKPV | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | K69 | ERCVIKILKPV | 1 | Arabidopsis thaliana | L46 | QLVRKLGRGKY | 3 | Homo sapiens, Mus musculus, Bos taurus | L46 | EIENKVGRGKY | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | L46 | EVVRKVGRGKY | 1 | Arabidopsis thaliana | M164 | KPHNVMIDHQQ | 3 | Homo sapiens, Mus musculus, Bos taurus | M164 | KPHNVMIDHKN | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | M164 | KPHNVMIDHQL | 1 | Arabidopsis thaliana | N162 | DVKPHNVMIDH | 5 | Homo sapiens, Saccharomyces cerevisiae (strain ATCC 204508 / S288c), Arabidopsis thaliana, Mus musculus, Bos taurus | R44 | DYQLVRKLGRG | 3 | Homo sapiens, Mus musculus, Bos taurus | R44 | DYEIENKVGRG | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | R44 | DYEVVRKVGRG | 1 | Arabidopsis thaliana | S52 | GRGKYSEVFEA | 3 | Homo sapiens, Mus musculus, Bos taurus | S52 | GRGKYSEVFQG | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | S52 | GRGKYSEVFEG | 1 | Arabidopsis thaliana | V54 | GKYSEVFEAIN | 3 | Homo sapiens, Mus musculus, Bos taurus | V54 | GKYSEVFQGVK | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | V54 | GKYSEVFEGKN | 1 | Arabidopsis thaliana | V67 | NNERVVVKILK | 3 | Homo sapiens, Mus musculus, Bos taurus | V67 | SKVKIVIKMLK | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | V67 | TNERCVIKILK | 1 | Arabidopsis thaliana | Y116 | ALVFEYINNTD | 3 | Homo sapiens, Mus musculus, Bos taurus | Y116 | ALVFEYVDNVD | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | Y116 | SLVFEFVNSVD | 1 | Arabidopsis thaliana |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |